###begin article-title 0
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
Variation in the UCP2 and UCP3 genes associates with abdominal obesity and serum lipids: The Finnish Diabetes Prevention Study
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(UCP2) </italic>
###xml 107 117 107 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2-UCP3 </italic>
###xml 181 188 181 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(UCP3) </italic>
###xml 403 404 401 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
We explored the associations of three variants in the uncoupling protein 2 (UCP2) gene, one variant in the UCP2-UCP3 intergenic region and five variants in the uncoupling protein 3 (UCP3) gene with obesity and diabetes related traits in subjects with impaired glucose tolerance participating in Finnish Diabetes Prevention Study. Altogether 507 overweight individuals (body mass index: 31.2 +/- 4.5 kg/m2, age: 55 +/- 7 years) for whom DNA was available were randomized to either an intensified diet and physical activity group or to a conventional care control group.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
We analysed the data from the baseline and annual follow-up visits from years 1, 2 and 3. Measurements of anthropometry, plasma glucose and serum insulin in oral glucose tolerance test, serum total cholesterol, HDL-cholesterol and triglycerides were included. The median follow-up time for type 2 diabetes incidence was 7 years. Genetic variants were screened by restriction fragment length polymorphism or Illumina method.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 18 28 18 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907 </italic>
###xml 223 245 223 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745, rs11235972 </italic>
###xml 249 259 249 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849 </italic>
###xml 266 271 266 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 367 394 367 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366, rs653529, rs15763</italic>
###xml 400 410 400 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745 </italic>
###xml 539 573 539 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366-G, rs653529-A, rs15763-G </italic>
###xml 577 589 577 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745-A </italic>
###xml 669 694 669 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907-G, rs11235972-A</italic>
###xml 700 712 700 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849-T </italic>
UCP3 gene variant rs3781907 was associated with increased serum total and LDL-cholesterol levels, at baseline and during the follow-up period. The same variant was associated with a higher risk of type 2 diabetes. Variants rs1726745, rs11235972 and rs1800849 in the UCP3 gene associated with serum total and LDL-cholesterol at baseline. Haploblock including variants rs659366, rs653529, rs15763, and rs1726745 was associated with measures of abdominal obesity at baseline and in the longitudinal analysis. The haplotype comprising alleles rs659366-G, rs653529-A, rs15763-G and rs1726745-A was associated with higher waist-to-hip ratio, and haplotype comprising alleles rs3781907-G, rs11235972-A, and rs1800849-T was associated with increased serum total and LDL-cholesterol concentrations.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 25 35 25 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2-UCP3 </italic>
Genetic variation in the UCP2-UCP3 gene cluster may act as a modifier increasing serum lipid levels and indices of abdominal obesity, and may thereby also contribute to the metabolic aberrations observed in obesity and type 2 diabetes.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 357 358 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 620 621 620 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 622 623 622 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 721 722 721 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 725 730 725 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 734 739 734 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 802 803 802 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 804 805 804 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 971 972 971 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
UCP2 is a member of the mitochondrial inner membrane carrier family that is expressed in a wide variety of tissues, for example in adipose tissue, skeletal muscle and pancreatic islets. The function of UCP2 is tissue-dependent, and its potential roles include the regulation of fat metabolism directly and indirectly, e.g. via effects on insulin secretion [1]. It also has a role in the limitation of reactive oxygen species (ROS) and macrophage-mediated immunity [2]. Recent studies have established UCP2 as a key component of beta cell glucose sensing, since it seems to regulate glucose-stimulated insulin secretion [1,3], and is also a critical link between obesity, beta cell dysfunction and type 2 diabetes (T2DM) [4]. UCP2 and UCP3 genes are located on chromosome 11q13 adjacent to one another [5,6]. In a recent meta-analysis of genome-wide linkage studies, suggestive evidence for chromosome 11q13.3-22.3 was observed for body mass index (BMI) -defined obesity [7].
###end p 11
###begin p 12
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 86 103 86 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-866 GA, rs659366</italic>
###xml 143 155 143 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ala55Val, CT</italic>
###xml 157 165 157 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs660339</italic>
###xml 218 225 218 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DelIns </italic>
###xml 369 370 369 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 387 396 387 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366 </italic>
###xml 439 441 439 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 800 802 800 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 835 844 835 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366 </italic>
###xml 882 885 882 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 983 985 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1050 1075 1050 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-866 GA, Val55Val, DelIns</italic>
###xml 723 728 <span type="species:ncbi:9606">women</span>
There are three common variants in the UCP2 gene, one located in the promoter region (-866 GA, rs659366), one is a missense variant in exon 4 (Ala55Val, CT, rs660339), and one locates in the untranslated exon 8 (45 bp DelIns in the 3'UTR). Their association with traits related to obesity, energy expenditure or T2DM remains controversial due to inconsistent findings [8-19]. Studies on rs659366 have demonstrated associations between the A allele and enhanced adipose tissue mRNA expression and decreased risk of obesity [17], increased energy expenditure [20], reduced beta cell function and higher risk of T2DM [14], lower insulin secretion [15], decreased lipid oxidation [16], increased preclinical atherosclerosis in women [21], and increased coronary heart disease risk [18]. Krempler et al. [14] have shown that the functional rs659366 variant, located in a multifunctional cis-regulatory site, acts as a binding site for a pancreatic transcription factor PAX6. Wang et al. [13] found that the heterozygous combination of the three variants (-866 GA, Val55Val, DelIns) was associated with increased BMI, triglyceride and fasting insulin levels.
###end p 12
###begin p 13
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 360 365 360 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 549 554 549 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 633 640 633 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-55 CT </italic>
###xml 641 650 641 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849</italic>
###xml 812 814 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 837 849 837 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849-T </italic>
###xml 924 926 924 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 996 998 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1146 1148 1146 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1165 1177 1165 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849-T </italic>
###xml 1237 1239 1237 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1297 1299 1297 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1348 1350 1348 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1351 1353 1351 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1379 1389 1379 1389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849 </italic>
###xml 1434 1436 1434 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1437 1439 1437 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1440 1442 1440 1442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 354 359 <span type="species:ncbi:9606">human</span>
###xml 543 548 <span type="species:ncbi:9606">human</span>
While the UCP2 gene is expressed in almost all tissues, expression of the UCP3 gene is mostly restricted to skeletal muscle and brown adipose tissue. Suggested functions of UCP3 include regulation of fatty acid metabolism, redox state, and ROS formation [22,23]. UCP3 seems to be involved in the protection of mitochondria against lipotoxicity [24]. The human UCP3 gene gives rise to two main alternative transcripts, the shorter one having a polyadenylation site in intron 6, which terminates approximately 50% of the transcripts. Therefore, human UCP3 exists as long (UCP3L) and short (UCP3S) forms [19]. A promoter region variant -55 CT (rs1800849) is potentially interesting since it is located only 6 bp apart from the TATA box and 4 bp from a DR1 site, which is a part of a retinoic acid response element [25]. In Pima Indians the rs1800849-T allele increased UCP3 mRNA expression in skeletal muscle compared with the C allele [25], and the expression level correlated negatively with BMI [26]. A direct correlation between sleeping metabolic rate and 24 h energy expenditure and the expression of UCP3 mRNA was also found in Pima Indians [26]. Moreover, the rs1800849-T allele was associated with higher waist-to-hip ratio (WHR) [27], decreased risk of T2DM, and atherogenic lipid profile [28], but associations with BMI were controversial [29-32]. No association between rs1800849 and body weight was seen in several studies [25,33-36].
###end p 13
###begin p 14
###xml 156 166 156 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2-UCP3 </italic>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
The aim of this study was to assess the impact of five previously unexplored variants in addition to the four above-mentioned known genetic variants in the UCP2-UCP3 gene cluster, either individually or as haplotypes, on obesity and T2DM related traits. The study subjects with impaired glucose tolerance (IGT) were prospectively followed in the Finnish Diabetes Prevention Study (DPS) [37,38].
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Subjects and research design
###end title 16
###begin p 17
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 227 228 227 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 738 740 736 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 682 685 <span type="species:ncbi:9606">men</span>
###xml 694 699 <span type="species:ncbi:9606">women</span>
###xml 983 995 <span type="species:ncbi:9606">participants</span>
###xml 1131 1136 <span type="species:ncbi:9606">human</span>
The DPS is a randomised, controlled, multicenter study carried out in Finland in 1993-2000. The DPS study design and methods used have been reported in detail elsewhere [37-39]. The main inclusion criteria were BMI over 25 kg/m2, age 40 to 64 years, IGT based on the mean values of two oral glucose tolerance tests (OGTTs). A total of 522 individuals with IGT were randomised into either a control group or an intensive, individualised diet and physical exercise intervention group stratified according to the clinic, sex, and the mean plasma glucose concentration two hours after an oral glucose load (7.8 to 9.4 or 9.5 to 11.0 mmol/l). DNA was available from 507 individuals (166 men and 341 women). Their mean BMI was 31.2 +/- 4.5 kg/m2 and age 55.3 +/- 7.1 years. At the baseline, 5% of the individuals were using cholesterol lowering medication. The study protocol was approved by the Ethics Committee of the National Public Health Institute in Helsinki, Finland, and the study participants gave written informed consent. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research.
###end p 17
###begin title 18
Measurements
###end title 18
###begin p 19
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 986 988 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1182 1184 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
A medical history was taken and a physical examination done at baseline and at each annual follow-up visit [38]. In this study, measurements from baseline to the 3-year examination were used, including height, weight, waist circumference (WC), hip circumference, serum lipid levels, and 2 h OGTT with glucose and insulin levels before (0 min) and after a 75 g glucose load (120 min) [38]. Plasma glucose was measured at each centre by standard methods. The serum insulin concentration was measured in a central laboratory by a radioimmunoassay method (Pharmacia, Uppsala, Sweden). The intra-assay coefficient of variation was 5.3% and the interassay coefficient of variation was 7.6%. Homeostasis model for insulin resistance (HOMA-IR) was calculated using the formula: fasting plasma glucose (mmol/l) x fasting serum insulin (mU/l)/22.5, and homeostasis model for insulin secretion (HOMA-IS) was calculated as 20 x fasting serum insulin (mU/l)/(fasting plasma glucose [mmol/l] - 3.5) [40]. Serum levels of total cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were measured by enzymatic assay in the central laboratory in Helsinki. Formula of Friedewald [41] was used to calculate the concentration of low density lipoprotein (LDL) cholesterol.
###end p 19
###begin title 20
DNA analysis
###end title 20
###begin p 21
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 207 225 207 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rs660339, rs659366</italic>
###xml 231 241 231 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849 </italic>
###xml 391 398 391 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DelIns </italic>
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
The single nucleotide polymorphisms (SNP) for genotype analysis were selected from the region spanning the UCP2 and UCP3 genes (~34.4 kb) by using the International HapMap database and Tagger software [42]. Rs660339, rs659366, and rs1800849 were forced in the selection procedure. The SNPs covered 86.2% of the genetic information of the studied region (r2>0.8). It should be noted that the DelIns variant of the UCP2 gene is not included in the database, since it is not a SNP but a 45 bp insertion.
###end p 21
###begin p 22
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366 </italic>
###xml 17 26 17 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs660339 </italic>
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 60 70 60 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849 </italic>
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 178 191 178 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MluI, HincII </italic>
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HaeIII</italic>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 289 296 289 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DelIns </italic>
###xml 311 316 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 407 416 407 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs653529 </italic>
###xml 450 455 450 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 461 502 461 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs15763, rs1726745, rs3781907, rs11235972</italic>
###xml 628 637 628 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745</italic>
###xml 647 687 647 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs653529, rs15763, rs3781907, rs11235972</italic>
The rs659366 and rs660339 variants of the UCP2 gene and the rs1800849 variant of the UCP3 gene were screened by the restriction fragment length polymorphism after digestion with MluI, HincII and HaeIII, respectively, with minor modifications to previously described methods [9,15,43]. The DelIns variant of the UCP2 gene was analysed by gel electrophoresis of the PCR-product. The intergenic region variant rs653529 and four variants locating in the UCP3 gene (rs15763, rs1726745, rs3781907, rs11235972) were genotyped by using the custom Golden Gate genotyping reagents and consumables (Illumina Inc, San Diego, CA). Only 501 (rs1726745) or 502 (rs653529, rs15763, rs3781907, rs11235972) subjects were successfully genotyped by Illumina. For other variants, n = 507.
###end p 22
###begin title 23
Statistical analysis
###end title 23
###begin p 24
###xml 805 812 805 812 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3-year </sub>
###xml 823 831 823 831 <sub xmlns:xlink="http://www.w3.org/1999/xlink">baseline</sub>
###xml 842 850 842 850 <sub xmlns:xlink="http://www.w3.org/1999/xlink">baseline</sub>
The data were analysed using the SPSS/WIN program version 14.0 (SPSS, Chigago, IL, USA). The normality of distributions of study variables was evaluated with the Kolmogorov-Smirnov test with Lilliefors' correction, and appropriate transformation was used when necessary. For variables with skewed distribution, Kruskal-Wallis test was used. Univariate analysis of variance was used to compare the effect of the gene variants on continuous variables. Adjustment for age, gender and BMI was done, when appropriate. In addition, serum lipoprotein and lipid concentrations were adjusted for the use of cholesterol-lowering medication as well. Chi square test was used in comparison of categorical variables. The relative changes in HOMA-IS from baseline to three years were calculated as follows: [(parameter 3-year - parameterbaseline)/parameterbaseline] x 100%. Longitudinal changes were examined using repeated measures of General Linear Model. Homogeneity of variances was tested using Levene's test. Cox regression analysis, adjusted for the study group, baseline weight, weight change and baseline fasting plasma glucose, was performed to evaluate whether the gene variants predicted the development of T2DM.
###end p 24
###begin p 25
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
Linkage disequilibrium (LD) statistics were calculated by Haploview software [44] and haplotype analysis was done by THESIAS 3.1 [45], which is based on the stochastic-EM algorithm. Haplotype analyses of the quantitative variables were adjusted for age, gender and BMI, when appropriate. The survival analysis for haplotypes was adjusted for the study group, baseline weight, weight change and baseline fasting plasma glucose.
###end p 25
###begin p 26
###xml 2 4 2 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p-</italic>
###xml 178 180 177 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0 </sub>
###xml 217 219 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 290 291 284 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 524 526 513 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">q </italic>
###xml 567 569 556 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
A p-value < 0.05 was considered statistically significant. Correction for multiple hypothesis testing was performed with false discovery rate (FDR) using Q-value 1.0 software. pi0 was estimated with bootstrap method [46] using lambda range from 0 to 0.9 by 0.05. Due to the distribution of p-values, the lambda was set to 0 for correcting the results of Cox regression. Essentially, this is a conservative way of calculating FDR and thereby produces the estimate implicit in the Benjamini and Hochberg methodology. In text, q stands for FDR, and is reported for each p < 0.05 and should be interpreted as minimum FDR that is incurred when calling that test significant. Data are given as means +/- SD, unless otherwise indicated.
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
Genotype and allele frequencies and LD
###end title 28
###begin p 29
###xml 104 105 104 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 302 303 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 329 330 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 391 393 391 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 439 450 439 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs11235972 </italic>
###xml 454 464 454 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849 </italic>
###xml 517 519 517 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 763 770 763 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DelIns </italic>
###xml 774 783 774 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs660339 </italic>
###xml 799 808 799 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 gene</italic>
###xml 828 856 828 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366, rs653529, rs15763 </italic>
###xml 860 870 860 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745 </italic>
###xml 877 882 877 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 886 891 886 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 928 950 928 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907, rs11235972 </italic>
###xml 954 964 954 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849 </italic>
###xml 971 976 971 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
The genotype frequencies of the nine gene variants were consistent with the Hardy-Weinberg equilibrium (p-values ranging from 0.065 to 0.952), and did not differ between the study groups. Location of the variants in the UCP2 and UCP3 genes and their minor allele frequencies and LD statistics (D' and r2) are presented in Figure 1 and Table 1. D' values were between 0.053 and 1.0, whereas r2 varied from 0.002 to 0.979. Although variants rs11235972 and rs1800849 were in strong linkage disequilibrium (D' = 1.0 and r2 = 0.979), no completely redundant variants were observed; thus all nine variants were included in subsequent association analysis. Based on solid spine of LD, haplotype analysis was done separately for three haplotype blocks, block 1 including DelIns and rs660339 variants of the UCP2 gene, block 2 including rs659366, rs653529, rs15763 and rs1726745 of the UCP2 and UCP3 genes, and block 3 covering variants rs3781907, rs11235972 and rs1800849 of the UCP3 gene.
###end p 29
###begin p 30
###xml 54 56 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 100 105 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
Pairwise linkage disequilibrium, presented as D' and r2 values, among the nine variants in UCP2 and UCP3 genes (haploblocks are shown bolded)
###end p 30
###begin p 31
Major/minor alleles, and the frequencies of the minor alleles of the corresponding variants are indicated next to each variant identification number
###end p 31
###begin p 32
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 0 101 0 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Schematic representation of the <italic>UCP2 </italic>and <italic>UCP3 </italic>genes indicating the locations of the analysed variants</bold>
Schematic representation of the UCP2 and UCP3 genes indicating the locations of the analysed variants. Grey boxes, coding region; white boxes, UTR; dotted line, intergenic region of ~17 kb.
###end p 32
###begin title 33
Baseline characteristics of subjects
###end title 33
###begin p 34
###xml 191 200 191 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs660339 </italic>
###xml 211 215 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 273 282 273 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366 </italic>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 359 371 359 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs660339-CC </italic>
###xml 375 387 375 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366-AA </italic>
###xml 454 466 454 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs660339-CC </italic>
###xml 470 482 470 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366-GG </italic>
###xml 551 560 551 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs653529 </italic>
###xml 624 626 624 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA</italic>
###xml 660 664 660 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
No significant differences were observed among the genotypes regarding body weight, BMI, fasting and 2-h insulin levels, HOMA-IR or HOMA-IS. Fasting and 2-h glucose levels differed among the rs660339 genotypes (p/q 0.006/0.006 and 0.025/0.010, respectively), and among the rs659366 genotypes (p/q 0.007/0.006 and 0.025/0.010, respectively). Specifically, the rs660339-CC and rs659366-AA homozygotes had the highest fasting glucose concentrations and the rs660339-CC and rs659366-GG homozygotes had the highest 2-h glucose concentrations. In addition, rs653529 associated with 2-h glucose level, so that the individuals with AA-genotype had the highest values (p/q 0.028/0.010), but the associations with glucose were not dependent on the allele dosage.
###end p 34
###begin p 35
###xml 134 162 134 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rs659366, rs653529, rs15763 </italic>
###xml 166 176 166 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745 </italic>
###xml 209 213 209 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 300 321 300 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366-AA, rs653529</italic>
###xml 322 324 322 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG</italic>
###xml 326 333 326 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs15763</italic>
###xml 334 337 334 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA </italic>
###xml 341 350 341 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745</italic>
###xml 351 354 351 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG </italic>
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 511 530 511 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366, rs653529 </italic>
###xml 534 543 534 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745</italic>
###xml 578 596 578 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs653529, rs15763 </italic>
###xml 600 610 600 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745 </italic>
###xml 617 618 617 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 630 637 630 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DelIns </italic>
###xml 650 655 650 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 694 701 694 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DelDel </italic>
###xml 746 750 746 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
Four gene variants in the haploblock 2 associated with indices of abdominal obesity, namely WC, WHR and waist-to-height ratio (WHtR). Rs659366, rs653529, rs15763 and rs1726745 associated with WHR at baseline (p/q 0.048/0.014, 0.009/0.006, 0.018/0.010 and 0.031/0.010, respectively), as subjects with rs659366-AA, rs653529-GG, rs15763-AA and rs1726745-GG genotypes had the lowest WHR (Table 2). Although less consistent, associations were also seen between these variants and WC and WHtR. WC was associated with rs659366, rs653529 and rs1726745, whereas WHtR was associated with rs653529, rs15763 and rs1726745 (Table 2). Also the DelIns variation in UCP2 associated with WHR, subjects with the DelDel genotype having the highest WHR at baseline (p/q 0.017/0.256).
###end p 35
###begin p 36
###xml 43 53 43 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2-UCP3 </italic>
Associations of representative SNPs in the UCP2-UCP3 gene region with indices of abdominal obesity at the baseline
###end p 36
###begin p 37
Data are means +/- SD
###end p 37
###begin p 38
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aUnivariate ANOVA, adjusted for age, gender, BMI
###end p 38
###begin p 39
WC, waist circumference; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio
###end p 39
###begin p 40
###xml 0 33 0 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rs1726745, rs3781907, rs11235972 </italic>
###xml 37 47 37 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849 </italic>
###xml 134 143 134 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745</italic>
###xml 144 146 144 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG</italic>
###xml 148 157 148 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907</italic>
###xml 158 160 158 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG</italic>
###xml 162 172 162 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs11235972</italic>
###xml 173 176 173 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA </italic>
###xml 180 193 180 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849-TT </italic>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 386 390 386 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 551 560 551 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907</italic>
###xml 561 564 561 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG </italic>
###xml 574 578 574 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 650 660 650 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907 </italic>
###xml 687 688 687 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 700 710 700 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907 </italic>
###xml 714 724 714 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs11235972</italic>
###xml 894 903 894 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745</italic>
###xml 909 918 909 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849</italic>
###xml 972 982 972 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745 </italic>
Rs1726745, rs3781907, rs11235972 and rs1800849 were associated with serum total cholesterol and LDL-cholesterol levels. Subjects with rs1726745-GG, rs3781907-GG, rs11235972-AA and rs1800849-TT genotypes had the highest serum total cholesterol concentrations among the variants (p/q 0.022/0.010, 0.005/0.006, 0.032/0.010 and 0.050/0.014, respectively), as well as serum LDL-cholesterol (p/q 0.005/0.006, 0.004/0.006, 0.045/0.014 and 0.071/0.018, respectively). Moreover, the total cholesterol-to-HDL-cholesterol ratio was highest for the subjects with rs3781907-GG genotype (p/q 0.045/0.013). Baseline characteristics of the DPS subjects according to rs3781907 are presented in the Table 3. Regarding rs3781907 and rs11235972, the results on lipids and lipoproteins remained unchanged, if the individuals using cholesterol lowering medication (n = 25) were excluded from the analyses. Regarding rs1726745, and rs1800849, the results were statistically significant only for rs1726745 association with LDL-cholesterol, if the individuals using cholesterol lowering medication were excluded.
###end p 40
###begin p 41
###xml 100 110 100 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907 </italic>
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
Baseline characteristics and conversion to type 2 diabetes (T2DM) according to the genotypes of SNP rs3781907 at UCP3 gene
###end p 41
###begin p 42
Data are means +/- SD
###end p 42
###begin p 43
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4 6 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
achi2 test
###end p 43
###begin p 44
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
b Univariate ANOVA, adjusted for age and sex (anthropometric measurements), for age, sex and BMI (glucose, insulin), or for age, sex, BMI, and the use of cholesterol lowering medication (lipids)
###end p 44
###begin p 45
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
c Kruskal-Wallis test
###end p 45
###begin title 46
The 3-year changes
###end title 46
###begin p 47
###xml 55 66 55 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs653529-GG</italic>
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs15763</italic>
###xml 76 79 76 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA </italic>
###xml 83 92 83 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745</italic>
###xml 93 96 93 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG </italic>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 226 227 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 321 329 321 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs15763 </italic>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 373 381 373 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs15763 </italic>
###xml 385 395 385 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745 </italic>
###xml 396 400 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
Longitudinal analysis of WHR showed that subjects with rs653529-GG, rs15763-AA and rs1726745-GG genotypes had the lowest WHR throughout the 3-year follow-up (p/q 0.025/0.030, 0.039/0.030 and 0.035/0.030, respectively) (Figure 2). Longitudinal analyses of WC and WHtR showed similar results, with WC being associated with rs15763 (p/q 0.030/0.030) and WHtR associating with rs15763 and rs1726745 (p/q 0.009/0.030, 0.040/0.030, respectively).
###end p 47
###begin p 48
###xml 56 65 56 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs653529 </italic>
###xml 70 78 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs15763 </italic>
###xml 87 97 87 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745 </italic>
###xml 111 115 111 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 0 169 0 169 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Waist-to-hip ratio from baseline to year 3 according to <italic>rs653529 </italic>(a), <italic>rs15763 </italic>(b), and <italic>rs1726745 </italic>(c) variants, <italic>p/q </italic>0.025/0.030, 0.039/0.030 and 0.035/0.030, respectively</bold>
Waist-to-hip ratio from baseline to year 3 according to rs653529 (a), rs15763 (b), and rs1726745 (c) variants, p/q 0.025/0.030, 0.039/0.030 and 0.035/0.030, respectively. Data are mean +/- SEM.
###end p 48
###begin p 49
###xml 70 79 70 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907</italic>
###xml 80 83 80 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA </italic>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 235 248 235 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907-AA </italic>
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 425 438 425 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907-GG </italic>
###xml 474 478 474 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 588 601 588 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907-GG </italic>
###xml 629 633 629 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
Longitudinal changes in serum cholesterol levels were associated with rs3781907-AA genotype having the lowest total cholesterol (p/q 0.020/0.030) and LDL-cholesterol (p/q 0.010/0.030) throughout the years 0-3 (Figure 3). Subjects with rs3781907-AA genotypes also had the lowest serum triglyceride levels, but this was seen only in the control group (p/q 0.039/0.030). HDL-cholesterol level was lowest among the subjects with rs3781907-GG genotype in the intervention group (p/q 0.041/0.030). Furthermore, the total cholesterol-to-HDL cholesterol ratio was highest among subjects with the rs3781907-GG genotype in the entire DPS (p/q 0.015/0.030). All these results remained significant if the individuals using cholesterol lowering medication were excluded.
###end p 49
###begin p 50
###xml 98 108 98 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907 </italic>
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 134 138 134 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 0 179 0 179 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Serum total cholesterol (a) and LDL-cholesterol (b) levels, from baseline to year 3, according to <italic>rs3781907 </italic>variant of the <italic>UCP3 </italic>gene, <italic>p/q </italic>0.020/0.030 and 0.010/0.030, respectively</bold>
Serum total cholesterol (a) and LDL-cholesterol (b) levels, from baseline to year 3, according to rs3781907 variant of the UCP3 gene, p/q 0.020/0.030 and 0.010/0.030, respectively. Data are mean +/- SEM.
###end p 50
###begin p 51
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 84 110 84 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DelIns, rs660339, rs659366</italic>
###xml 143 152 143 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs653529 </italic>
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 169 176 169 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs15763</italic>
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 430 435 430 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
The 3-year change in HOMA-IS was associated similarly with all three UCP2 variants (DelIns, rs660339, rs659366), the intergenic region variant rs653529 and UCP3 variant rs15763, showing increased values for wild-type subjects, intermediate for heterozygous and the lowest values for homozygous subjects (p/q 0.004/0.304, 0.016/0.325, 0.037/0.325, 0.018/0.325 and 0.016/0.325, respectively), whereas no association with other four UCP3 variants was found.
###end p 51
###begin title 52
Haplotype analysis
###end title 52
###begin p 53
###xml 248 258 246 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DelC, InsT</italic>
###xml 264 268 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DelT</italic>
###xml 296 312 294 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAGA, GAGG, AGAG</italic>
###xml 318 322 316 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGGG</italic>
###xml 363 371 361 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGC, GAT</italic>
###xml 377 380 375 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AAT</italic>
###xml 389 390 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
In order to confirm the associations with serum lipids and WHR, haplotype analysis was performed separately for blocks 1, 2, and 3. Only the haplotypes with frequency >/= 0.05 were included in the analysis; thus, block 1 consisted of 3 haplotypes (DelC, InsT, and DelT), block 2 of 4 haplotypes (GAGA, GAGG, AGAG, and AGGG) and block 3 of 3 different haplotypes (AGC, GAT, and AAT) (Table 4).
###end p 53
###begin p 54
###xml 102 106 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2</italic>
###xml 107 112 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
Frequencies and associations of the major haplotypes (frequency >/= 0.05) of three haploblocks in the UCP2-UCP3 gene region
###end p 54
###begin p 55
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
a The most frequent haplotype is the reference, with which the others are compared
###end p 55
###begin p 56
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
b Adjusted for age and gender
###end p 56
###begin p 57
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
c Adjusted for age, gender and BMI
###end p 57
###begin p 58
upward arrow, higher in comparison with the reference haplotype; downward arrow, lower in comparison with the reference haplotype
###end p 58
###begin p 59
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGAG </italic>
###xml 102 107 102 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAGA </italic>
###xml 108 110 108 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAT </italic>
###xml 185 187 185 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 217 219 217 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 283 286 283 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGC</italic>
###xml 312 316 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AAT </italic>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGC </italic>
In block 2 the haplotype AGAG showed lower WHR at baseline when compared with the reference haplotype GAGA (p = 0.050). In block 3 the haplotype GAT had higher serum total cholesterol (p = 0.006) and LDL-cholesterol (p = 0.024) at baseline when compared with the reference haplotype AGC. Moreover, the haplotype AAT showed a greater decrease (0-3 years) in LDL-cholesterol level compared with the reference haplotype AGC during the 3-year follow-up (p = 0.037). No associations were seen for the haplotypes in the haploblock 1.
###end p 59
###begin title 60
Conversion to T2DM
###end title 60
###begin p 61
###xml 155 164 155 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907</italic>
###xml 165 167 165 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G </italic>
###xml 238 241 238 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA </italic>
###xml 301 302 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 303 305 303 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">q </italic>
###xml 445 447 445 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 489 492 489 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA </italic>
###xml 578 581 578 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AG </italic>
###xml 585 588 585 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG </italic>
###xml 613 617 613 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p/q </italic>
###xml 637 638 637 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 712 715 712 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG </italic>
###xml 748 751 748 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA </italic>
During a median follow-up of seven years 185 individuals (75 in the intervention group and 110 in the control group) developed T2DM. The subjects with the rs3781907-G allele were at a higher risk for T2DM when compared with subjects with AA genotype, with hazard ratio (HR) of 1.48 (95%CI 1.09-2.00), p/q 0.011/0.100. We also analysed the genotype x study group interaction for the diabetes conversion, but it was not statistically significant (p = 0.447). The percentage of subjects with AA genotype converting to T2DM was 33%, whereas it was 38% and 48% for the subjects with AG and GG genotypes, respectively (p/q 0.039/0.394) (Table 3). The percentages of converters were similar for both study groups, with GG genotype showing the highest and AA genotype showing the lowest percentages of converters.
###end p 61
###begin p 62
###xml 62 74 62 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 InsIns </italic>
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Del </italic>
###xml 177 178 177 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 179 181 179 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">q </italic>
Surprisingly, subjects in the intervention group carrying the UCP2 InsIns genotype were at a higher risk compared with subjects with Del allele, with HR 2.53 (95%CI 1.11-5.73), p/q 0.027/0.243. Such a risk increment was not seen in the control group, nor in the entire DPS. No genotype x study group interaction was seen here either.
###end p 62
###begin p 63
The conversion to T2DM during the follow-up did not differ significantly among the other gene variants. In the haplotype analysis, none of the haplotypes studied were associated with an increased risk of T2DM.
###end p 63
###begin title 64
Discussion
###end title 64
###begin p 65
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 221 226 221 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 564 565 564 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
In the present study we evaluated whether the UCP2 and UCP3 genes act as modifiers for obesity and diabetes related risk factors. This study provides new evidence concerning associations between genetic variations in the UCP2 and UCP3 genes and serum lipid concentrations as well as indices of abdominal obesity, both being characteristics of the metabolic syndrome. Previous studies have explored effects of these genes on various traits in several populations, with inconsistent results concerning associations with lipid levels and WHR/abdominal obesity (Table 5). The study subjects in the DPS were overweight with IGT, and thus at a high risk to develop T2DM. The advantages of this study population are i) homogenous, carefully selected and phenotyped subjects, ii) prospective study design with extensive longitudinal follow-up data on key variables, iii) confirmation of new T2DM diagnosis based upon two subsequent OGTTs, and iv) Finnish population with only few founding members and thus genetically relatively homogeneous. On the other hand, one drawback for genetic analyses in the DPS is the limited power due to relatively small sample-size, particularly if the analyses are carried out in smaller sub-groups. In this study, stratification to different groups was unnecessary, since the associations with WHR and lipid levels were observed in the entire DPS study population.
###end p 65
###begin p 66
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
Associations of UCP2 and UCP3 gene variants with waist-to-hip ratio (WHR) and serum lipid concentrations in previous studies
###end p 66
###begin p 67
###xml 81 98 81 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs653529, rs15763</italic>
###xml 100 121 100 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745, rs3781907 </italic>
###xml 125 136 125 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs11235972 </italic>
###xml 194 206 194 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907-G </italic>
###xml 477 489 477 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907-G </italic>
###xml 501 506 501 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 </italic>
###xml 523 532 523 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849</italic>
###xml 592 601 592 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907</italic>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 774 776 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 827 829 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 845 847 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 848 850 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 865 867 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 868 870 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 907 909 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 926 936 926 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849 </italic>
###xml 1130 1132 1130 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1385 1395 1385 1395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907 </italic>
To our knowledge, this is the first study exploring effects of the gene variants rs653529, rs15763, rs1726745, rs3781907 and rs11235972 on several metabolic traits. Interestingly, subjects with rs3781907-G allele experienced a higher risk of T2DM and dyslipidemia compared with subjects homozygous for the common allele. The conversion to T2DM and serum levels of total cholesterol, LDL-cholesterol and total cholesterol-to-HDL-cholesterol ratio were modified by the dosage of rs3781907-G allele. The UCP3 promoter variant rs1800849, which is located in the same haploblock and is in LD with rs3781907, has been previously shown to be associated with an increased [47] or decreased [28] risk of T2DM, increased skeletal muscle UCP3 mRNA expression [25], higher total, LDL- [28] and HDL-cholesterol concentrations [32], higher [29] or lower BMI [30-32], higher WHR [27,43] and higher fat mass and lean mass [48]. In this study rs1800849 was associated with higher total cholesterol and LDL-cholesterol concentration at baseline, both as alleles and also as a member of the haploblock 3, in line with findings from earlier studies [28]. Interestingly, all the haploblock 3 variants were associated with total and LDL-cholesterol at the baseline, although the most consistent association with various serum lipoprotein and lipid concentrations at baseline and longitudinally was seen for rs3781907 that was also a risk factor for conversion to T2DM. FDR was low for these associations, which further provides support for our findings. However, as no previous studies with this variant exist, a confirmation of the present results is needed in other populations.
###end p 67
###begin p 68
###xml 166 204 166 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366, rs653529, rs15763, rs1726745</italic>
###xml 226 254 226 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs653529, rs15763, rs1726745</italic>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 600 610 600 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2-UCP3 </italic>
###xml 1192 1202 1192 1202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745 </italic>
###xml 1316 1326 1316 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907 </italic>
Although none of the gene variants were associated with weight or BMI, variants in the haploblock 2 associated with several indices of abdominal obesity at baseline (rs659366, rs653529, rs15763, rs1726745) and longitudinally (rs653529, rs15763, rs1726745). Although waist circumference and BMI are strongly correlated [49], WC, WHR and WHtR are all independent obesity-related predictors of cardiovascular risk independent of BMI [50], and together with serum lipid concentrations they are simple clinical surrogate markers of excess visceral/ectopic fat [49]. In this study the genetic variation in UCP2-UCP3 gene cluster seemed to be also associated with both serum lipids and indices of abdominal obesity as well. The single-marker associations were mostly haploblock specific, so that the markers from haploblock 2 were associated with central obesity indices, whereas the markers from the haploblock 3 were associated with serum cholesterol concentrations. The results of haplotype analyses were in line with the results of single marker analyses, but they did not reveal a haplotype that would explain the associations substantially better than the individual markers. We conclude that rs1726745 explains most of the associations (both baseline and longitudinal) seen in haploblock 2 with central obesity, and rs3781907 explains most of the associations seen in haploblock 3 with total and LDL-cholesterol concentrations. However, it is difficult to suggest whether the causative variant truly is one of the studied markers or simply a SNP that is in complete disequilibrium with them.
###end p 68
###begin p 69
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 44 52 44 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-866 GA </italic>
###xml 53 61 53 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366</italic>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 349 354 349 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 </italic>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 602 613 602 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366-A </italic>
###xml 682 684 682 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G </italic>
###xml 845 856 845 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366-A </italic>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
As for the functional UCP2 promoter variant -866 GA (rs659366), previous studies have found that it is associated with a reduced prevalence of obesity [17], reduced risk of coronary artery disease [51], reduced [52] or increased [14] risk of T2DM, lower insulin secretion [15,53], reduced insulin sensitivity [54], a decreased [13] or increased [17]UCP2 mRNA level in adipose tissue, higher oxidative stress and risk of coronary heart disease [18], decreased HDL-cholesterol [55], and increased serum triglyceride, total cholesterol and LDL-cholesterol levels [56]. In our study, the subjects with the rs659366-A allele had lower WC and WHR at baseline, compared with subjects with G allele, both individually as well as a member of haploblock 2. Also the insulin secretion, measured by HOMA-IS, seemed to be decreased most in the subjects with rs659366-A allele during the 3-year follow-up, although no differences were seen at the baseline. These findings are in line with previous findings [15,17,53]. FDR was low for the associations with abdominal obesity indices thus supporting it, but high for the associations with HOMA-IS, which of course weakens the strength of this finding.
###end p 69
###begin p 70
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 211 227 211 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP2 (rs659366-A</italic>
###xml 236 253 236 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3 (rs1800849-T</italic>
###xml 371 382 371 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366-A </italic>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 521 531 521 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849 </italic>
###xml 832 833 832 833 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
UCP2 has been said to act as adiposity angel and diabetes devil [57], whereas increased expression of UCP3 has been suggested to be associated with weight loss success [58]. The promoter area variant alleles in UCP2 (rs659366-A) and in UCP3 (rs1800849-T) have been shown to increase gene expression, and thus these alleles might protect against obesity. In our study the rs659366-A allele were associated with lower WHR and WC at baseline, in line with findings by Esterbauer et al. [17]. However, no association between rs1800849 and obesity was seen in this study. Neither were the promoter area variants associated with risk of T2DM. This could be due to the relatively small study population, and also the genetic 'makeup' varies from one population to another. Furthermore, as the mean BMI of the study population was 31.2 kg/m2, the 'obese character' may also have masked the effects of these genetic variants, which may explain the lack of association with obesity.
###end p 70
###begin title 71
Conclusion
###end title 71
###begin p 72
###xml 102 114 102 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs3781907-G </italic>
###xml 296 297 296 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 324 333 324 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745</italic>
###xml 334 335 334 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 337 347 337 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs11235972</italic>
###xml 348 350 348 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 354 366 354 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1800849-T </italic>
###xml 509 530 509 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs659366-AA, rs653529</italic>
###xml 531 533 531 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG</italic>
###xml 535 542 535 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs15763</italic>
###xml 543 546 543 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AA </italic>
###xml 550 559 550 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rs1726745</italic>
###xml 560 562 560 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GG</italic>
In summary, several novel findings were detected and they need to be confirmed. The subjects with the rs3781907-G allele had higher levels of serum total and LDL-cholesterol concentrations at baseline and at longitudinal follow-up, and a higher risk of T2DM, when compared with the subjects with A-allele. The subjects with rs1726745-G, rs11235972-A and rs1800849-T alleles had also higher serum total and LDL-cholesterol concentrations compared with those carrying the more common alleles. Several variants (rs659366-AA, rs653529-GG, rs15763-AA and rs1726745-GG) were associated with lower abdominal obesity indices, at baseline and longitudinally.
###end p 72
###begin title 73
Competing interests
###end title 73
###begin p 74
The authors declare that they have no competing interests.
###end p 74
###begin title 75
Authors' contributions
###end title 75
###begin p 76
###xml 298 301 <span type="species:ncbi:68887?0.7968036529680366">TTV</span>
TS participated in designing and performing the genotyping and statistical analysis and drafted the manuscript; LP participated in designing the genetic studies and haplotype analysis and writing the manuscript; AMT and MK participated in statistical analysis and revising the manuscript; JL, JGE, TTV, SA, PIP, SKK, and ML contributed to study design and coordination and revised the manuscript; JT and MU are the principal investigators of the study and participated in writing the manuscript. All authors read and approved the final manuscript.
###end p 76
###begin title 77
Pre-publication history
###end title 77
###begin p 78
The pre-publication history for this paper can be accessed here:
###end p 78
###begin p 79

###end p 79
###begin title 80
Acknowledgements
###end title 80
###begin p 81
This work has been financially supported by grants from the Academy of Finland (no. 40758 to M.U.; 38387 and 46558 to J.T.; 73566 to S.K-K.), the EVO-fund of the Kuopio University Hospital (no. 5179 and 5198 to M.U.), the Ministry of Education of Finland, and the Finnish Diabetes Research Foundation, Yrjo Jahnsson Foundation, Juho Vainio Foundation, Sigrid Juselius Foundation and Finnish Cultural Foundation. The technical assistance of Minna Kiuttu, Tuomas Makinen and Paivi Turunen is acknowledged.
###end p 81
###begin article-title 82
Regulation of insulin secretion by uncoupling protein
###end article-title 82
###begin article-title 83
###xml 47 51 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production
###end article-title 83
###begin article-title 84
Inhibition of UCP2 expression reverses diet-induced diabetes mellitus by effects on both insulin secretion and action
###end article-title 84
###begin article-title 85
Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes
###end article-title 85
###begin article-title 86
Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia
###end article-title 86
###begin article-title 87
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human uncoupling protein-3 gene. Genomic structure, chromosomal localization, and genetic basis for short and long form transcripts
###end article-title 87
###begin article-title 88
Meta-Analysis of Genome-wide Linkage Studies in BMI and Obesity
###end article-title 88
###begin article-title 89
Association between uncoupling protein polymorphisms (UCP2-UCP3) and energy metabolism/obesity in Pima indians
###end article-title 89
###begin article-title 90
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Molecular screening of uncoupling protein 2 gene in patients with noninsulin-dependent diabetes mellitus or obesity
###end article-title 90
###begin article-title 91
An uncoupling protein 2 gene variant is associated with a raised body mass index but not Type II diabetes
###end article-title 91
###begin article-title 92
Genetic variation at the uncoupling protein 1, 2 and 3 loci and the response to long-term overfeeding
###end article-title 92
###begin article-title 93
Lack of association between the uncoupling protein-2 Ala55Val gene polymorphism and phenotypic features of the Metabolic Syndrome
###end article-title 93
###begin article-title 94
Uncoupling protein-2 polymorphisms in type 2 diabetes, obesity, and insulin secretion
###end article-title 94
###begin article-title 95
###xml 126 132 <span type="species:ncbi:9606">humans</span>
A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans
###end article-title 95
###begin article-title 96
A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects
###end article-title 96
###begin article-title 97
The common -866 g/a polymorphism in the promoter of uncoupling protein 2 is associated with increased carbohydrate and decreased lipid oxidation in juvenile obesity
###end article-title 97
###begin article-title 98
###xml 106 112 <span type="species:ncbi:9606">humans</span>
A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans
###end article-title 98
###begin article-title 99
###xml 31 34 <span type="species:ncbi:9606">men</span>
###xml 79 82 <span type="species:ncbi:9606">men</span>
Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2
###end article-title 99
###begin article-title 100
Uncoupling proteins: functional characteristics and role in the pathogenesis of obesity and Type II diabetes
###end article-title 100
###begin article-title 101
Genetic variation in UCP2 (uncoupling protein-2) is associated with energy metabolism in Pima Indians
###end article-title 101
###begin article-title 102
###xml 93 98 <span type="species:ncbi:9606">women</span>
Associations of the UCP2 gene locus with asymptomatic carotid atherosclerosis in middle-aged women
###end article-title 102
###begin article-title 103
The role of uncoupling proteins in pathophysiological states
###end article-title 103
###begin article-title 104
UCP2 and UCP3 in muscle controlling body metabolism
###end article-title 104
###begin article-title 105
Mitochondrial uncoupling protein 3 and its role in cardiac- and skeletal muscle metabolism
###end article-title 105
###begin article-title 106
A novel polymorphism in the proximal UCP3 promoter region: effect on skeletal muscle UCP3 mRNA expression and obesity in male non-diabetic Pima Indians
###end article-title 106
###begin article-title 107
Skeletal muscle uncoupling protein 3 expression is a determinant of energy expenditure in Pima Indians
###end article-title 107
###begin article-title 108
Uncoupling protein 1 and 3 polymorphisms are associated with waist-to-hip ratio
###end article-title 108
###begin article-title 109
An uncoupling protein 3 gene polymorphism associated with a lower risk of developing Type II diabetes and with atherogenic lipid profile in a French cohort
###end article-title 109
###begin article-title 110
###xml 101 107 <span type="species:ncbi:9606">humans</span>
A genetic variation in the 5' flanking region of the UCP3 gene is associated with body mass index in humans in interaction with physical activity
###end article-title 110
###begin article-title 111
Linkage and association analyses of the UCP3 gene with obesity phenotypes in Caucasian families
###end article-title 111
###begin article-title 112
###xml 41 46 <span type="species:ncbi:9606">human</span>
Uncoupling protein 3 genetic variants in human obesity: the c-55t promoter polymorphism is negatively correlated with body mass index in a UK Caucasian population
###end article-title 112
###begin article-title 113
The common -55 C/T polymorphism in the promoter region of the uncoupling protein 3 gene reduces prevalence of obesity and elevates serum high-density lipoprotein cholesterol levels in the general Japanese population
###end article-title 113
###begin article-title 114
Variations in the uncoupling protein-3 gene are associated with specific obesity phenotypes
###end article-title 114
###begin article-title 115
The effects of uncoupling protein 3 haplotypes on obesity phenotypes and very low-energy diet-induced changes among overweight Korean female subjects
###end article-title 115
###begin article-title 116
A prevalent polymorphism in the promoter of the UCP3 gene and its relationship to body mass index and long term body weight change in the Danish population
###end article-title 116
###begin article-title 117
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Lack of association of -55CT polymorphism of UCP3 gene with fat distribution in obese patients
###end article-title 117
###begin article-title 118
The Finnish Diabetes Prevention Study
###end article-title 118
###begin article-title 119
Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme
###end article-title 119
###begin article-title 120
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
###end article-title 120
###begin article-title 121
Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test
###end article-title 121
###begin article-title 122
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
###end article-title 122
###begin article-title 123
Efficiency and power in genetic association studies
###end article-title 123
###begin article-title 124
###xml 116 121 <span type="species:ncbi:9606">women</span>
Evidence that single nucleotide polymorphism in the uncoupling protein 3 (UCP3) gene influences fat distribution in women of European and Asian origin
###end article-title 124
###begin article-title 125
Haploview: analysis and visualization of LD and haplotype maps
###end article-title 125
###begin article-title 126
A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm
###end article-title 126
###begin article-title 127
Statistical significance for genomewide studies
###end article-title 127
###begin article-title 128
###xml 107 110 <span type="species:ncbi:9606">men</span>
Variation in the UCP2-UCP3 gene cluster predicts the development of type 2 diabetes in healthy middle-aged men
###end article-title 128
###begin article-title 129
Genetic variation in uncoupling protein 3 is associated with dietary intake and body composition in females
###end article-title 129
###begin article-title 130
Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk
###end article-title 130
###begin article-title 131
Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis
###end article-title 131
###begin article-title 132
###xml 131 134 <span type="species:ncbi:9606">men</span>
The common -866G>A variant in the promoter of UCP2 is associated with decreased risk of coronary artery disease in type 2 diabetic men
###end article-title 132
###begin article-title 133
The common -866G/A polymorphism in the promoter region of the UCP-2 gene is associated with reduced risk of type 2 diabetes in Caucasians from Italy
###end article-title 133
###begin article-title 134
###xml 148 156 <span type="species:ncbi:9606">patients</span>
Uncoupling protein 2 promoter polymorphism -866G/A affects its expression in beta-cells and modulates clinical profiles of Japanese type 2 diabetic patients
###end article-title 134
###begin article-title 135
###xml 44 49 <span type="species:ncbi:9606">human</span>
The -866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of type 2 diabetes
###end article-title 135
###begin article-title 136
###xml 109 114 <span type="species:ncbi:9606">women</span>
Association of UCP2 and UCP3 gene polymorphisms with serum high-density lipoprotein cholesterol among Korean women
###end article-title 136
###begin article-title 137
###xml 70 78 <span type="species:ncbi:9606">patients</span>
A polymorphism in the promoter of UCP2 gene modulates lipid levels in patients with type 2 diabetes
###end article-title 137
###begin article-title 138
Uncoupling protein 2: Adiposity angel and diabetes devil?
###end article-title 138
###begin article-title 139
Uncoupling protein-3: clues in an ongoing mitochondrial mystery
###end article-title 139

